FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer
NANJING, China, Nov. 22, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global...
TAILG Represents the Industry at COP29, Advancing South-South Cooperation with Low-Carbon Solutions
BAKU, Azerbaijan, Nov. 21, 2024 /PRNewswire/ -- Recently, the United Nations Climate Change Conference (COP29) was held in Baku, Azerbaijan. As a representative of the electric mobility industry, which provides clean energy solutions for climate...